Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00650091

Acronym

PANTHER-IPF

Enrollment

264

Registered

2008-04-01

Start date

2009-10-31

Completion date

2014-01-31

Last updated

2015-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Fibrosis

Keywords

Idiopathic Pulmonary Fibrosis, Prednisone, Azathioprine, NAC, N-acetylcysteine

Brief summary

Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three groups - receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone, or placebo - in a 1:1:1 ratio.

Detailed description

IPF is a disease with widespread and permanent scarring of lung tissue which eventually results in death. Individuals with IPF may experience breathing difficulties, cough, chest pain, and a decreased exercise capacity. Although the cause of IPF is unknown, it may be a result of an inflammatory response to an unknown substance. NAC, an antioxidant that is effective at loosening up mucus that forms in the lungs, may improve lung function. The purpose of this study is to evaluate the effectiveness of NAC at preventing the loss of lung function in people with IPF. In the initial double-blind, placebo-controlled trial, subjects who have idiopathic pulmonary fibrosis with mild-to-moderate impairment in pulmonary function are randomly assigned to receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone; or placebo. After safety concerns were identified by the data and safety monitoring board, the three-drug regimen was stopped by the National Heart, Lung, and Blood Institute (NHLBI) on October 14, 2011, and a clinical alert was issued. After a brief period of interruption for modification of the protocol and approval by the institutional review boards, patients continued to be recruited for the acetylcysteine group and the placebo group and were followed for the pre-specified duration of 60 weeks. Study visits will occur at baseline and Weeks 4, 15, 30, 45, and 60. At all study visits, a physical exam and blood collection will occur. At selected visits, the following study procedures will occur: lung function testing; urine collection; a 6-minute walk test, and questionnaires to assess health status, breathing, and quality of life. Participants will record medication usage and symptoms in a daily diary.

Interventions

DRUGN-acetylcysteine (NAC)

Participants will receive 600 mg of NAC three times a day.

DRUGPlacebo

Participants will receive placebo each day.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Forced vital capacity (FVC) greater than or equal to 50% of predicted value * Diffusion capacity (DLCO) greater than or equal to 30% of predicted value * Diagnosis of IPF by modified American Thoracic Society (ATS) criteria in the 48 months before study entry

Exclusion criteria

* History of clinically significant environmental exposure known to cause pulmonary fibrosis * Diagnosis of connective tissue disease as the likely cause of the interstitial disease * Extent of emphysema greater than the extent of fibrotic change (i.e., honeycombing, reticular changes) on high resolution computed tomography (HRCT) scan * Forced expiratory volume in 1 second (FEV1)/FVC ratio less than 0.65 at the time of screening (post-bronchodilator) * Partial pressure of arterial oxygen (PaO2) less than 55 mm Hg (less than 50 mm Hg at Denver study site) * Residual volume greater than 120% predicted at the time of screening (post-bronchodilator) * Evidence of active infection * Significant bronchodilator response on screening spirometry, defined as change in FEV1 greater than or equal to 12% and absolute change greater than 200 mL OR change in FVC greater than or equal to 12% and absolute change greater than 200 mL * Screening and baseline FVC measurements (in liters, post-bronchodilator) differing by 11% * Listed for lung transplantation * History of unstable or deteriorating cardiac disease * Heart attack, coronary artery bypass, or angioplasty in the 6 months before study entry * Unstable angina pectoris or congestive heart failure requiring hospitalization in the 6 months before study entry * Uncontrolled arrhythmia * Severe uncontrolled high blood pressure * Known HIV or hepatitis C * Known cirrhosis and chronic active hepatitis * Active substance and/or alcohol abuse * Pregnant or breastfeeding * Women of childbearing potential who are not using a medically approved means of contraception * Any clinically relevant lab abnormalities, including the following: 1. Creatinine greater than twice the upper limit of normal (ULN) 2. Hematology outside of specified limits 1. White blood cells less than 3,500/mm3 2. Hematocrit less than 25% or greater than 59% 3. Platelets less than 100,000 mm3 at the time of screening 3. Any of the following liver function test criteria above specified limits 1. Total bilirubin greater than twice the ULN 2. Aspartate (AST) or alanine aminotransferases (ALT) greater than 1.5 the ULN 3. Alkaline phosphatase greater than three times the ULN 4. Albumin less than 3.0 mg/dL at the time of screening * Known hypersensitivity to study medication * Any condition other than IPF that, in the opinion of the site PI, is likely to result in death in the 1 year after study entry * Any condition that, in the judgment of the PI, might cause participation in this study to be detrimental or makes the person a poor candidate for the study

Design outcomes

Primary

Measure	Time frame	Description
Overall Change in Forced Vital Capacity	Measured as the estimated change from baseline to Week 60	Change from Baseline in Forced Vital Capacity at 60 weeks (units in liters)

Secondary

Measure	Time frame	Description
Disease Progression	Measured at Week 60	The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression. The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline.
Acute Exacerbations	Measured at Week 60	The following 3 criteria will define acute exacerbations in subjects with acute worsening of their respiratory conditions: 1\. Clinical (all of the following required): A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization). B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea. C) No pneumothorax.
Respiratory Infections	Measured at Week 60	—
Number of Participants With Maintained Forced Vital Capacity Response	Measured at Week 60	Maintained forced vital capacity response was a binary variable taking on a value of 1 for participants with higher FVC % predicted at week 60 compared to baseline.

Countries

United States

Participant flow

Recruitment details

Initial Study Design: Subjects are randomly assigned to receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone; or placebo. Amended Study Design: The three-drug regimen was removed from the protocol due to safety concerns on 10/14/2011. Subjects are randomly assigned to acetylcysteine or placebo.

Pre-assignment details

Participants in the Pred/AZA/NAC group were discontinued and not re-randomized in the amended study.

Participants by arm

Arm	Count
N-Acetylcysteine Participants will receive N-acetylcysteine (NAC) for 60 weeks. N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.	133
Placebo Participants will receive placebo for 60 weeks. Placebo: Participants will receive placebo each day.	131
Total	264

Withdrawals & dropouts

Period	Reason	FG000	FG001
Amended Study Design	Adverse Event	1	4
Amended Study Design	Lung transplantation	4	2
Amended Study Design	Other	1	3
Amended Study Design	Physician Decision	5	0
Amended Study Design	Withdrawal by Subject	12	11

Baseline characteristics

Characteristic	N-Acetylcysteine	Placebo	Total
Age, Continuous	68.3 years STANDARD_DEVIATION 6.4	67.2 years STANDARD_DEVIATION 8.2	67.8 years STANDARD_DEVIATION 8.3
Sex: Female, Male Female	26 Participants	33 Participants	59 Participants
Sex: Female, Male Male	107 Participants	98 Participants	205 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	123 / 133	117 / 131	68 / 77	61 / 78
serious Total, serious adverse events	25 / 133	20 / 131	24 / 77	8 / 78

Outcome results

Primary